JP3272743B2 - Placenta or liver extract having stable SOD activity and external preparation composition containing the same - Google Patents
Placenta or liver extract having stable SOD activity and external preparation composition containing the sameInfo
- Publication number
- JP3272743B2 JP3272743B2 JP09772091A JP9772091A JP3272743B2 JP 3272743 B2 JP3272743 B2 JP 3272743B2 JP 09772091 A JP09772091 A JP 09772091A JP 9772091 A JP9772091 A JP 9772091A JP 3272743 B2 JP3272743 B2 JP 3272743B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- placenta
- sod activity
- liver
- external preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Landscapes
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明は、胎盤または肝臓の抽出
液をプロテアーゼで酵素分解し、分子量10,000以
下の物質を除去して得られる安定なSOD活性を有する
抽出液(以下単に抽出液という場合がある)およびそれ
を含有することを特徴とする安全な外用剤組成物に関す
るものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an extract having stable SOD activity (hereinafter simply referred to as extract) obtained by enzymatically decomposing a placenta or liver extract with a protease to remove substances having a molecular weight of 10,000 or less. And a safe external preparation composition characterized by containing it.
【0002】[0002]
【従来の技術】ラジカルスカベンジャーであるSOD
(スーパーオキシドジィスムターゼ)は、人間を含めて
広く動物および微生物に存在する一種の生体防御酵素で
あり、細胞内において有害で反応性の高い活性酵素、例
えばスーパーオキシドラジカル(O2 ) , ヒドロキシル
ラジカル( ・OH)等の活性酸素種の濃度を低下させる
ことから、生命の恒常性維持に係わる重要な酵素として
注目されている。2. Description of the Related Art SOD which is a radical scavenger
(Superoxide dismutase) is a kind of biological defense enzyme that exists widely in animals and microorganisms, including humans, and is an active enzyme that is harmful and highly reactive in cells, such as superoxide radical (O 2 ) and hydroxyl. Since it reduces the concentration of reactive oxygen species such as radicals (.OH), it has attracted attention as an important enzyme involved in maintaining homeostasis of life.
【0003】例えば、胎盤エキスにSODが含まれてい
ることは公知であり(特開昭61−277626号公
報)、ヒト胎盤からSODを単離する製造法も知られて
いる(特開昭56−102787号公報、特開昭57−
155991号公報)。[0003] For example, it is known that placenta extract contains SOD (Japanese Patent Application Laid-Open No. 61-277626), and a production method for isolating SOD from human placenta is also known (Japanese Patent Application Laid-Open No. Sho 56). Japanese Patent Application Laid-open No.
No. 155991).
【0004】また、SODには強い抗炎症作用や皮膚の
紅斑抑制作用があることが、ラット・カラゲニン足浮腫
試験などによって認められており〔Oyanagui.
Y.:Inhibition of superoxi
de anions atthe prostagla
ndin phase of carrageenan
foot−oedema.Biochem.Phar
macol.25:1465−1472,1976:A
kira Y.,Yoshiki M.,Miyach
i I.,J.Dermtol.,14,569(19
87)〕、関連の技術も開示されている(例えば、特開
昭56−7720号公報など)。[0004] In addition, it has been confirmed that SOD has a strong anti-inflammatory effect and an inhibitory effect on erythema of the skin by rat carrageenin foot edema test and the like [Oyanagui.
Y. : Inhibition of superoxi
de anions atthe prostagla
ndin phase of carrageenan
foot-oedema. Biochem. Phar
macol. 25: 1465-1472, 1976: A
kira Y. , Yoshiki M .; , Miyach
i I. , J. et al. Dermtol. , 14, 569 (19
87)], and related techniques are also disclosed (for example, Japanese Patent Application Laid-Open No. 56-7720).
【0005】さらに、SODの種々の特性を利用した化
粧料も知られている(例えば、特公昭59−10324
号公報、特開昭55−87712号公報など)。Further, cosmetics utilizing various characteristics of SOD are known (for example, Japanese Patent Publication No. 59-10324).
And Japanese Patent Application Laid-Open No. 55-87712).
【0006】[0006]
【発明が解決しようとする課題】しかしながら、SOD
は優れた特性があるにもかかわらず、本来不安定な酵素
であるため、特に水溶液の状態で保存した時にSOD活
性を失ったり、濁りが生じる等の問題があった。SUMMARY OF THE INVENTION However, SOD
Despite its excellent properties, it is inherently an unstable enzyme, and thus has problems such as loss of SOD activity and turbidity particularly when stored in an aqueous solution.
【0007】したがって、従来技術によって得られた原
料を、例えば化粧料の有効成分として配合しても、SO
Dそのものの効果が発揮されなかったり、色や臭いが経
時的に変化することなどによって商品価値を損なう問題
があるため、安定なSOD活性を有する原料や製剤の開
発が望まれていた。[0007] Therefore, even if the raw material obtained by the prior art is blended as an active ingredient of a cosmetic, for example,
Since there is a problem that the commercial value is impaired due to the effect of D itself not being exhibited or the color and odor changing over time, the development of raw materials and formulations having stable SOD activity has been desired.
【0008】本発明は、このような現状に鑑みてなされ
たもので、安定なSOD活性を有する胎盤または肝臓抽
出液およびそれを配合することを特徴とする外用剤組成
物を提供することを目的とするものである。[0008] The present invention has been made in view of such circumstances, and an object of the present invention is to provide a placenta or liver extract having stable SOD activity and an external preparation composition comprising the extract. It is assumed that.
【0009】[0009]
【課題を解決するための手段】本発明者らは鋭意研究の
結果、胎盤または肝臓の抽出液をプロテアーゼで酵素分
解し、酵素分解して得られる分子量10,000以下の
物質を除去することによって、安定なSODの活性を有
する抽出液が得られ、これを外用剤基剤に配合すること
で、SODの活性低下が著しく改善された外用剤組成物
が得られることを見出し本発明を完成した。Means for Solving the Problems As a result of intensive studies, the present inventors enzymatically decompose a placenta or liver extract with a protease and remove substances having a molecular weight of 10,000 or less obtained by the enzymatic decomposition. It was found that an extract having stable SOD activity was obtained, and by blending this with an external preparation base, an external preparation composition in which the decrease in SOD activity was significantly improved was obtained, and the present invention was completed. .
【0010】本発明の外用剤組成物に配合する抽出液
は、胎盤または肝臓に水、水とアルコールなどの有機溶
媒との混合溶媒を使用して一般の抽出法により抽出した
液に、SOD活性が失活しない一定のpH、温度条件下
でプロテアーゼを作用させ、蛋白質を酵素分解した後、
分子量10,000以下のものを除去することによって
得られる。なお、プロテアーゼによる酵素分解時間は、
後述する製造例からわかるように、少なくとも5時間を
要することによって安定なSOD活性を有するものが得
られる。The extract prepared in the external preparation composition of the present invention can be prepared by adding SOD activity to a liquid extracted from the placenta or liver by a general extraction method using water or a mixed solvent of water and an organic solvent such as alcohol. After a protease is allowed to act under a certain pH and temperature condition that does not cause inactivation,
It can be obtained by removing those having a molecular weight of 10,000 or less. The enzymatic degradation time of the protease is
As can be seen from the manufacturing examples described below, at least 5 hours
As a result, a product having stable SOD activity can be obtained.
Can be
【0011】本発明で使用する胎盤または肝臓の種類は
特に制限されないが、胎盤の場合は、ヒト,ウシ,ウ
マ,ブタなどが好適であり、肝臓の場合はウシ,ウマ,
ブタ,トリなどが好適に使用される。The type of placenta or liver used in the present invention is not particularly limited. For placenta, human, cow, horse, pig and the like are preferable, and for liver, bovine, horse, and horse.
Pigs, birds and the like are preferably used.
【0012】蛋白分解酵素を作用させる場合は、SOD
の活性を維持させる必要があることから、pHは5〜
9、好ましくは6.5〜8.5、温度は5〜50℃、好
ましくは20〜40℃の反応条件が良い。蛋白質を分解
する際に用いる酵素は、中性プロテアーゼ(例 アクチ
ナーゼE(科研製薬製))、パパイン、トリプシンが好
適に使用される。When a protease is used, SOD
It is necessary to maintain the activity of
The reaction conditions are preferably 9, preferably 6.5 to 8.5, the temperature is 5 to 50 ° C, and preferably 20 to 40 ° C. As the enzyme used for decomposing the protein, neutral protease (eg, actinase E (manufactured by Kaken Pharmaceutical)), papain, and trypsin are preferably used.
【0013】さらに、蛋白分解酵素液中からSODを不
安定にする要因を取り除くために、限外濾過や透析膜を
利用して濾過するなど通常の操作で分子量10,000
以下の物質を除去する。Further, in order to remove the factors that destabilize SOD from the proteolytic enzyme solution, a molecular weight of 10,000 is obtained by a usual operation such as ultrafiltration or filtration using a dialysis membrane.
Remove the following materials:
【0014】このようにして得られる本発明の抽出液
は、安定なSOD活性を有ししかも皮膚に対する刺激が
殆どないため、これを外用剤基剤に配合することによっ
て、臭いや色調の経時変化の少ない安定なSOD活性を
有する安全な外用剤組成物を提供することができる。The extract of the present invention thus obtained has a stable SOD activity and hardly causes irritation to the skin. Therefore, when the extract is added to an external preparation base, the odor and the color tone change over time. It is possible to provide a safe external preparation composition having a low SOD activity and a stable SOD activity.
【0015】本発明の抽出液を配合した製剤の剤型は、
外用の形態であれば特に制限はなく、医薬品や化粧料に
通常に用いられる剤型、例えば化粧水、クリーム、乳
液、パック、エッセンス、軟膏剤、乳剤など種々の基剤
を使用することができる。但し、クリームなどの製造工
程中、乳化時の長時間の高温加熱はSODの活性が損な
われることから好ましくなく、必ず45℃以下の条件で
抽出液を添加、攪拌することが望まれる。[0015] The dosage form of the preparation containing the extract of the present invention is
There is no particular limitation as long as it is an external use form, and various bases such as a lotion, a cream, an emulsion, a pack, an essence, an ointment, and an emulsion which are usually used for pharmaceuticals and cosmetics can be used. . However, during the production process of cream or the like, long-time high-temperature heating during emulsification is not preferable because the activity of SOD is impaired, and it is desirable to always add and stir the extract under conditions of 45 ° C. or lower.
【0016】本発明の抽出液を前記基剤に配合する場
合、外用剤の全量に対して0.01〜50.0%(重
量)で、好適には0.1〜30%(重量)が使用され
る。When the extract of the present invention is mixed with the above-mentioned base, it is used in an amount of 0.01 to 50.0% (weight), preferably 0.1 to 30% (weight), based on the total amount of the external preparation. used.
【0017】以下、実施例によって本発明を詳細に説明
する。Hereinafter, the present invention will be described in detail with reference to examples.
【0018】[0018]
製造例 1 ウシ胎盤1kgを冷生理食塩水で洗浄した後細切し、精
製水2kgを加え、30℃で3時間攪拌しながら抽出す
る。次に、これを遠心分離(8,000rpm、20分
間、5℃)後、上清液をとり弱塩基性(pH7.3)に
調整し、アクチナーゼE(科研製薬製)を加え、30℃
で5時間攪拌する。さらにこの溶液を酸性(pH4.
5)にし、遠心分離(8,000rpm、10分間、5
℃)後中性(pH7.0)にし、透析膜処理で分子量1
0,000以下の物質を取り除いてSOD活性10,5
00unit/mlを有するウシ胎盤抽出液を得た。Production Example 1 1 kg of bovine placenta is washed with cold physiological saline, cut into small pieces, 2 kg of purified water is added, and the mixture is extracted with stirring at 30 ° C. for 3 hours. Next, this was centrifuged (8,000 rpm, 20 minutes, 5 ° C.), and the supernatant was adjusted to weak basicity (pH 7.3), actinase E (manufactured by Kaken Pharmaceutical Co., Ltd.) was added, and 30 ° C.
And stir for 5 hours. Further, the solution was acidified (pH 4.
5) and centrifugation (8,000 rpm, 10 minutes, 5 minutes)
℃) and then neutralized (pH 7.0), and treated with a dialysis membrane to have a molecular weight of 1
SOD activity of 10,5 or less
A bovine placenta extract having 00 units / ml was obtained.
【0019】製造例 2 ウマ肝臓1kgを冷生理食塩水で洗浄した後細切し、精
製水3kgを加え、40℃で3時間攪拌しながら抽出す
る。次に、これを遠心分離(8,000rpm、20分
間、5℃)後、上清液をとり弱塩基性(pH8.0)に
調整し、アクチナーゼE(科研製薬製)を加え、20℃
で6時間攪拌する。さらにこの溶液を酸性(pH4.
5)にし、遠心分離(8,000rpm、10分間、5
℃)後中性(pH7.0)にし、限外濾過で分子量1
0,000以下の物質を取り除いてSOD活性25,0
00unit/mlを有するウマ肝臓抽出液を得た。Production Example 2 1 kg of horse liver was washed with cold physiological saline, cut into small pieces, 3 kg of purified water was added, and the mixture was extracted with stirring at 40 ° C. for 3 hours. Next, this was centrifuged (8,000 rpm, 20 minutes, 5 ° C.), and the supernatant was taken to adjust to weak basicity (pH 8.0), and actinase E (manufactured by Kaken Pharmaceutical) was added.
And stir for 6 hours. Further, the solution was acidified (pH 4.
5) and centrifugation (8,000 rpm, 10 minutes, 5 minutes)
℃) and then neutralized (pH 7.0), ultrafiltration with molecular weight 1
Remove SOD activity of 25.0 or less
An equine liver extract with 00 units / ml was obtained.
【0020】製造例 3 ブタ胎盤1kgを冷生理食塩水で洗浄した後細切し、精
製水とエタノール混液1:1)2kgを加え、30℃で
3時間攪拌しながら抽出する。次に、これを遠心分離
(8,000rpm、20分間、5℃)後、上清液を取
りパパインを加え、25℃で5時間攪拌する。さらにこ
の溶液を酸性(pH4.5)にし、遠心分離(8,00
0rpm、10分間、5℃)後中性(pH7.0)に
し、限外濾過で分子量10,000以下の物質を取り除
き、SOD活性3,000unit/mlを有するブタ
胎盤抽出液を得た。Production Example 3 1 kg of pig placenta is washed with cold physiological saline, cut into small pieces, 2 kg of purified water / ethanol mixture (1: 1) is added, and the mixture is extracted at 30 ° C. for 3 hours with stirring. Next, this is centrifuged (8,000 rpm, 20 minutes, 5 ° C.), the supernatant is taken, papain is added, and the mixture is stirred at 25 ° C. for 5 hours. Further, the solution was acidified (pH 4.5) and centrifuged (8,000).
The mixture was neutralized (pH 7.0) after 0 rpm for 10 minutes at 5 ° C., and substances having a molecular weight of 10,000 or less were removed by ultrafiltration to obtain a swine placenta extract having SOD activity of 3,000 units / ml.
【0021】製造例 4 ウシ肝臓1kgを冷生理食塩水で洗浄した後細切し、精
製水3kgを加え、35℃で3時間攪拌しながら抽出す
る。次に、これを遠心分離(8,000rpm、20分
間、5℃)後、上清液を取り、トリプシンを加え、15
℃で8時間攪拌する。さらにこの溶液を酸性(pH5.
0)にし、遠心分離後(8,000rpm、10分間、
5℃)中性(pH7.0)にし、透析膜を用いて分子量
10,000以下の物質を取り除いてSOD活性23,
000unit/mlを有するウシ肝臓抽出液を得た。Production Example 4 1 kg of bovine liver was washed with cold saline, cut into small pieces, 3 kg of purified water was added, and the mixture was extracted with stirring at 35 ° C. for 3 hours. Next, this was centrifuged (8,000 rpm, 20 minutes, 5 ° C.), the supernatant was taken out, and trypsin was added thereto.
Stir at 8 ° C. for 8 hours. Further, the solution was acidified (pH 5.
0), and after centrifugation (8,000 rpm, 10 minutes,
5 ° C.) Neutral (pH 7.0), remove substances having a molecular weight of 10,000 or less using a dialysis membrane, and
A bovine liver extract having 000 units / ml was obtained.
【0022】製造例 5 トリ肝臓1kgを冷生理食塩水で洗浄した後細切し、精
製水2.2kgおよびエタール0.8kgを加え、40
℃で3時間攪拌しながら抽出する。次に、これを遠心分
離(8,000rpm、20分間、5℃)後上清液を取
り、アクチナーゼEを加え、30℃で5時間攪拌する。
さらに、この溶液を酸性(pH4.5)にし、遠心分離
(8,000rpm、10分間、5℃)後中性(pH
7.0)にし、透析膜で分子量10,000以下の物質
を取り除き、SOD活性17,000unit/mlを
有するトリ肝臓抽出液を得た。Production Example 5 1 kg of chicken liver was washed with cold physiological saline, cut into small pieces, and 2.2 kg of purified water and 0.8 kg of ethanol were added.
Extract with stirring at 3 ° C. for 3 hours. Next, this is centrifuged (8,000 rpm, 20 minutes, 5 ° C.), and the supernatant is collected, actinase E is added, and the mixture is stirred at 30 ° C. for 5 hours.
Further, the solution was acidified (pH 4.5), centrifuged (8,000 rpm, 10 minutes, 5 ° C.), and neutralized (pH
7.0), and a substance having a molecular weight of 10,000 or less was removed with a dialysis membrane to obtain an avian liver extract having an SOD activity of 17,000 units / ml.
【0023】次に、本願発明の酵素分解液ならびにこれ
を配合した製剤の試験結果(効果データ)を示す。Next, test results (effect data) of the enzyme-decomposed solution of the present invention and a formulation containing the same are shown.
【0024】試験例 (1)胎盤または肝臓抽出液のSOD活性 以下の実験の結果、本発明の各臓器抽出液のSOD活性
は非常に安定であることがわかった。Test Examples (1) SOD Activity of Placenta or Liver Extract The following experiment showed that the SOD activity of each organ extract of the present invention was very stable.
【0025】a)臓器エキスの抽出法 臓器(胎盤または肝臓)1kgをミンチにし、精製水2
kgを加え、40℃で約3時間攪拌抽出する。この抽出
液を遠心分離(8,000rpm、20分間、5℃)
し、上清液を10%水酸化ナトリウム水溶液でpHを弱
塩基性(7.5)に調整し、アクチナーゼEを添加し、
30℃で5時間攪拌しながら、酵素分解する。これを弱
酸性(約pH5.0)にし、一夜放置後、遠心分離
(8,000rpm、10分間、5℃)して上清液をと
る。さらに、この液のpHを中性(7.0)にして分子
量10,000以下の物質を取り除き、試験液とする。A) Extraction method of organ extract 1 kg of an organ (placenta or liver) is minced and purified water 2
Then, the mixture is stirred and extracted at 40 ° C. for about 3 hours. This extract is centrifuged (8,000 rpm, 20 minutes, 5 ° C.)
The supernatant was adjusted to a slightly basic pH (7.5) with a 10% aqueous sodium hydroxide solution, and actinase E was added thereto.
The enzyme is decomposed while stirring at 30 ° C. for 5 hours. This is made weakly acidic (about pH 5.0), left overnight, and centrifuged (8,000 rpm, 10 minutes, 5 ° C.) to collect the supernatant. Further, the pH of the solution is adjusted to neutral (7.0), and substances having a molecular weight of 10,000 or less are removed to prepare a test solution.
【0026】b)SOD活性測定法 0.05M炭酸ナトリウム緩衝液(pH10.2)の
2.4mlに、3mMキサンチン、3mMエデト酸二ナ
トリウム、0.15%牛血清アルブミン、0.75mM
ニトロブルーテトラゾリウムの各試液0.1mlを加え
る。これに精製水で適当希釈の臓器抽出エキス試料0.
1mlを加え、25℃で10分間放置後、キサンチンオ
キシダーゼ(約1unit/ml)0.1mlを加え
て、25℃でインキュベートする。B) SOD activity measurement method In 2.4 ml of 0.05 M sodium carbonate buffer (pH 10.2), 3 mM xanthine, 3 mM disodium edetate, 0.15% bovine serum albumin, 0.75 mM
Add 0.1 ml of each test solution of nitro blue tetrazolium. To this, an organ extract extract sample appropriately diluted with purified water.
After adding 1 ml and leaving at 25 ° C. for 10 minutes, 0.1 ml of xanthine oxidase (about 1 unit / ml) is added, and the mixture is incubated at 25 ° C.
【0027】20分後、6mM塩化銅溶液0.1mlを
加えて反応を停止させ、560nmの吸光度を測定す
る。After 20 minutes, 0.1 ml of a 6 mM copper chloride solution is added to stop the reaction, and the absorbance at 560 nm is measured.
【0028】吸光度の50%阻害する濃度を1単位とす
る。The concentration that inhibits the absorbance by 50% is defined as one unit.
【0029】c)臓器抽出液のSOD活性の経時安定性 上記の試験液(本発明の抽出液)、比較液(上記試験例
において酵素分解および分子量分画をしないものを比較
例1とし、酵素分解はするが分子量分画をしないものを
比較例2とした)を5,20,45℃で1か月間保存
し、2,10,16,30日目に外観の変化(沈澱、濁
り、異臭の有無)を観察するとともに、SOD活性の変
化を測定した。C) Stability over time of SOD activity of organ extract The above-mentioned test solution (extract of the present invention) and a comparative solution (the above-mentioned test example, which was not subjected to enzymatic decomposition and molecular weight fractionation, was referred to as Comparative Example 1; The compound which decomposed but did not undergo molecular weight fractionation was designated as Comparative Example 2) was stored at 5, 20, 45 ° C for 1 month, and changed its appearance (precipitation, turbidity, off-odor) on days 2, 10, 16, and 30. And the change in SOD activity were measured.
【0030】結果を表1〜表4に示す。The results are shown in Tables 1 to 4.
【0031】[0031]
【表1】 [Table 1]
【0032】[0032]
【表2】 [Table 2]
【0033】[0033]
【表3】 [Table 3]
【0034】[0034]
【表4】 [Table 4]
【0035】以上のように、本発明の各臓器抽出液は、
すべての温度条件においてSOD活性の低下は殆ど見ら
れず、安定であることが確認された。As described above, each organ extract of the present invention contains
Under all temperature conditions, a decrease in SOD activity was hardly observed, and it was confirmed that the SOD activity was stable.
【0036】また、外観の変化も認められなかった。No change in appearance was observed.
【0037】次に外用剤組成物の具体的な処方例を示す
が、本発明はかかる実施例にのみに限定されるものでは
ない。Next, specific formulation examples of the external preparation composition will be shown, but the present invention is not limited to only these examples.
【0038】〔処方例〕 処方例1(クリーム) (重量%) ポリオキシエチレンオレイルエーテル(P.O.E.O) 1.60 モノステアリン酸グリセリン 3.00 サラシミツロウ 2.80 セタノール 3.00 ステアリン酸 1.75 流動パラフィン 7.10 パルソール1789 0.50 スクワラン 4.50 グリセリン 2.50 カーボポール940 0.08 クレワットN 0.01 製造例3で製造したブタ胎盤抽出液 0.10 精製液 73.06 この他に少量の香料および防腐剤を添加した。Formulation Example Formulation Example 1 (Cream) (% by weight) Polyoxyethylene oleyl ether (POEO) 1.60 Glycerin monostearate 3.00 Salami beeswax 2.80 Cetanol 3.00 Stearic acid 1.75 Liquid paraffin 7.10 Parsol 1789 0.50 Squalane 4.50 Glycerin 2.50 Carbopol 940 0.08 Crewat N 0.01 Pig placenta extract prepared in Production Example 3 0.10 Purified liquid 73 0.06 In addition, small amounts of perfume and preservatives were added.
【0039】 処方例2(乳液) (重量%) スクワラン 5.00 ワセリン 2.00 ミツロウ 0.50 ソルビタンセスキオレイン酸エステル 1.20 プロピレングリコール 5.00 エタノール 5.00 カルボキシビニルポリマー(1%水溶液) 20.00 水酸化カリウム 0.10 製造例1で製造したウシ胎盤抽出液 10.00 精製液 51.60 この他に少量の香料、防腐剤および酸化防止剤を添加し
た。Formulation Example 2 (Emulsion) (% by weight) Squalane 5.00 Vaseline 2.00 Beeswax 0.50 Sorbitan sesquioleate 1.20 Propylene glycol 5.00 Ethanol 5.00 Carboxyvinyl polymer (1% aqueous solution) 20.00 Potassium hydroxide 0.10 Bovine placenta extract prepared in Production Example 1 10.00 Purified liquid 51.60 In addition, small amounts of fragrances, preservatives and antioxidants were added.
【0040】処方例3(乳液) 処方例2において、「製造例1で製造したウシ胎盤抽出
液」の代わりに、「製造例2で製造したウマ肝臓抽出
液」を用いた処方を処方例3とした。Formulation Example 3 (Emulsion) In Formulation Example 2, a formulation using “Horse liver extract manufactured in Preparation Example 2” instead of “Bovine placenta extract manufactured in Preparation Example 1” was prepared. And
【0041】処方例4(乳液) 処方例2において、「製造例1で製造したウシ胎盤抽出
液」の代わりに、「製造例5で製造したトリ肝臓抽出
液」を用いた処方を処方例4とした。Formulation Example 4 (Emulsion) In Formulation Example 2, instead of "Bovine placenta extract manufactured in Preparation Example 1", a formulation using "Avian liver extract manufactured in Preparation Example 5" was prepared. And
【0042】 処方例5(化粧水) (重量%) クエン酸 0.40 炭酸カルシウム 0.20 エタノール 5.00 プロピレングリコール 9.00 製造例4で製造したウシ肝臓抽出液 30.00 精製液 55.40 この他に少量の香料および防腐剤を添加した。Formulation Example 5 (Lotion) (% by weight) Citric acid 0.40 Calcium carbonate 0.20 Ethanol 5.00 Propylene glycol 9.00 Bovine liver extract manufactured in Production Example 4 30.00 Purified solution 55. 40 In addition, small amounts of fragrances and preservatives were added.
【0043】 処方例6(パック) (重量%) ビーガム 5.00 スクワラン 2.00 プロピレングリコール 5.00 酸化亜鉛 10.00 エタノール 5.00 製造例2で製造したウマ肝臓抽出液 2.00 精製水 61.00 この他に少量の香料および防腐剤を添加した。Formulation Example 6 (pack) (% by weight) Vegum 5.00 Squalane 2.00 Propylene Glycol 5.00 Zinc Oxide 10.00 Ethanol 5.00 Horse Liver Extract Produced in Production Example 2 2.00 Purified Water 61.00 A small amount of perfume and preservative were added.
【0044】 処方例7(エッセンス) (重量%) カルボキシビニルポリマー(1%水溶液) 10.00 グリセリン 20.00 エタノール 1.00 ヒアルロン酸ナトリウム(1%水溶液) 10.00 製造例2で製造したウマ肝臓抽出液 10.00 精製水 49.00 この他に少量の香料および防腐剤を添加した。Formulation Example 7 (Essence) (% by weight) Carboxyvinyl polymer (1% aqueous solution) 10.00 Glycerin 20.00 Ethanol 1.00 Sodium hyaluronate (1% aqueous solution) 10.00 Horse produced in Production Example 2 Liver extract 10.00 Purified water 49.00 In addition, a small amount of flavor and preservative were added.
【0045】 処方例8(ヘアトニック) (重量%) エタノール(95%) 75.00 グリセリン 5.00 製造例4で製造したウシ肝臓抽出液 5.00 精製水 15.00 この他に少量の香料および防腐剤を添加した。Formulation Example 8 (hair tonic) (% by weight) Ethanol (95%) 75.00 Glycerin 5.00 Bovine liver extract prepared in Production Example 4 5.00 Purified water 15.00 In addition to a small amount of fragrance And preservatives were added.
【0046】[0046]
【発明の効果】本発明によれば、安定なSOD活性を有
する種々の胎盤または肝臓抽出液を得ることができ、こ
れを自明の外用剤基剤に配合することにより、SOD本
来の作用がいかんなく発揮される、安全で、商品価値の
損なわれない外用剤組成物が提供される。According to the present invention, various placenta or liver extracts having stable SOD activity can be obtained, and by blending them with a trivial external preparation base, the original action of SOD can be improved. The present invention provides an external preparation composition that is safe, does not lose its commercial value, and is exhibited without any problems.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI C12N 9/50 C12N 9/76 9/76 C12P 21/06 C12P 21/06 A61K 37/50 (56)参考文献 特開 昭64−55143(JP,A) 特開 平2−300137(JP,A) 特開 昭63−284133(JP,A) 特開 昭62−135434(JP,A) 特開 昭64−20084(JP,A) 特開 昭62−130684(JP,A) 特開 昭56−32422(JP,A) 特開 昭56−7720(JP,A) 特開 昭55−87712(JP,A) 特開 昭57−155991(JP,A) 特開 昭56−102787(JP,A) 特開 昭64−63383(JP,A) 特開 昭61−277626(JP,A) 特公 昭59−10324(JP,B2) 特表 昭62−501472(JP,A) 特表 昭63−501473(JP,A) (58)調査した分野(Int.Cl.7,DB名) A61K 35/50 A61K 7/00 A61K 7/06 A61K 35/407 ────────────────────────────────────────────────── ─── Continued on the front page (51) Int.Cl. 7 Identification code FI C12N 9/50 C12N 9/76 9/76 C12P 21/06 C12P 21/06 A61K 37/50 (56) References JP-A-64 JP-A-2-300137 (JP, A) JP-A-63-284133 (JP, A) JP-A-62-135434 (JP, A) JP-A-64-20084 (JP, A) JP-A-62-130684 (JP, A) JP-A-56-32422 (JP, A) JP-A-56-7720 (JP, A) JP-A-55-87712 (JP, A) 155991 (JP, A) JP-A-56-102787 (JP, A) JP-A-64-63383 (JP, A) JP-A-61-277626 (JP, A) JP-B-59-10324 (JP, B2) Tokuyo Sho 62-501472 (JP, A) Tokuyo Sho 63-501473 (JP, A) (58) Fields investigated (Int. Cl. 7 , DB name) A61K 35/50 A61K 7/00 A61K 7/06 A61K 35/407
Claims (2)
間プロテアーゼで酵素分解し、分子量10,000以下
の物質を除去して得られる安定なSOD活性を有する抽
出液。1. Placenta or liver extract at least 5 hours
An extract having stable SOD activity, obtained by enzymatically decomposing with an intermediate protease to remove substances having a molecular weight of 10,000 or less.
間プロテアーゼで酵素分解し、分子量10,000以下
の物質を除去して得られる安定なSOD活性を有する抽
出液を含有することを特徴とする外用剤組成物。2. Placenta or liver extract at least 5 hours
And enzymatic degradation between protease, external composition characterized by containing an extract having a stable SOD activity obtained by removing a molecular weight of 10,000 or less of material.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP09772091A JP3272743B2 (en) | 1991-04-26 | 1991-04-26 | Placenta or liver extract having stable SOD activity and external preparation composition containing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP09772091A JP3272743B2 (en) | 1991-04-26 | 1991-04-26 | Placenta or liver extract having stable SOD activity and external preparation composition containing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0578252A JPH0578252A (en) | 1993-03-30 |
JP3272743B2 true JP3272743B2 (en) | 2002-04-08 |
Family
ID=14199731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP09772091A Expired - Fee Related JP3272743B2 (en) | 1991-04-26 | 1991-04-26 | Placenta or liver extract having stable SOD activity and external preparation composition containing the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3272743B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108179141A (en) * | 2018-03-28 | 2018-06-19 | 西安瑞仁生物技术有限公司 | A kind of plant rennet extracting method and plant rennet obtained |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4976629B2 (en) * | 2001-09-27 | 2012-07-18 | コンビ株式会社 | Skin promotion agent |
CN105456291A (en) * | 2015-12-31 | 2016-04-06 | 甘肃普尔康药业有限公司 | Large-scale production technology of liver extract |
SG10202108899XA (en) * | 2017-02-23 | 2021-09-29 | Zeria Pharmaceutical Co Ltd | Anti-inflammatory agent |
JP6739472B2 (en) * | 2018-05-30 | 2020-08-12 | 株式会社粧薬研究所 | Agent containing horse placenta extract as active ingredient |
KR102503124B1 (en) * | 2022-08-18 | 2023-02-23 | 주식회사 에이바이오머티리얼즈 | Method for preparing sheep placenta extract containing high content of amino acid and cosmetic composition comprising the extract |
-
1991
- 1991-04-26 JP JP09772091A patent/JP3272743B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108179141A (en) * | 2018-03-28 | 2018-06-19 | 西安瑞仁生物技术有限公司 | A kind of plant rennet extracting method and plant rennet obtained |
Also Published As
Publication number | Publication date |
---|---|
JPH0578252A (en) | 1993-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3532244B2 (en) | Mucopolysaccharide fragmentation inhibitor, active oxygen scavenger and cosmetic | |
US4959213A (en) | Pharmaceutical composition for treatment and/or prevention of diseases of the skin involving an inflammatory process | |
JP2597084B2 (en) | Cosmetic composition | |
JPH0925225A (en) | Skin external agent and production of active component for the agent | |
JPH09143063A (en) | Composition suitable for external use | |
EP0414605A1 (en) | Pasty aqueous pharmaceutical compositions | |
JPH05230100A (en) | Protein fraction, its isolation, effective substance concentrate containing said fraction and preparation for skin care and/or medical treatment of inflammatory skin | |
EP1908455A1 (en) | Hair care preparation | |
JP3504205B2 (en) | External preparation for skin | |
KR101353628B1 (en) | Compounding ingredients for basic cosmetics and basic cosmetics | |
CN103547254B (en) | Containing the wrinkle improvement compositions from the composition of Placenta Hominis | |
JP2000229832A (en) | Skin lotion | |
JP2001122757A (en) | Active oxygen scavenger, antioxidant and cosmetic | |
JPH07277939A (en) | Skin external preparation | |
JP3272743B2 (en) | Placenta or liver extract having stable SOD activity and external preparation composition containing the same | |
JP3263409B2 (en) | External preparation for skin | |
JP2009084212A (en) | Involucrin production promoter | |
JPH069422A (en) | Promoter for biosynthesis of hyaluronic acid | |
JP2002284632A (en) | Extinction substance for superoxide anion extracted from sake lees as effective component | |
EP0909557A1 (en) | Use of honey as an agent for decreasing micro-organisms adhesion | |
JP3413220B2 (en) | Skin roughness improver | |
JPS61205204A (en) | External preparation for skin | |
JP3708485B2 (en) | Composition for external use | |
JP2000212058A (en) | Skin cosmetic, active oxygen eliminator, esterase inhibitor, and collagenase inhibitor | |
JP3105664B2 (en) | External preparation for skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20020115 |
|
LAPS | Cancellation because of no payment of annual fees |